US, EU and Australia reveal positive outcomes from pilot GCP and API inspection projects
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration and its counterparts in Europe and Australia have revealed positive findings from two pilot programmes aimed at collaborating on inspections of clinical trials and active pharmaceutical ingredient manufacturing facilities1.